DBV Technologies reported $29.52M in Current Liabilities for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
DBV Technologies DBVT:US USD 29.52M 1.13M
Acadia Pharmaceuticals ACAD:US USD 125.63M 9.06M
Alnylam Pharmaceuticals ALNY:US USD 767.92M 4.88M
Amarin AMRN:US USD 287.36M 74.22M
Biomarin Pharmaceutical BMRN:US USD 588.88M 67.86M
Esperion Therapeutics ESPR:US USD 92.31M 9.96M
Galectin Therapeutics GALT:US USD 9.59M 1.3M
Halozyme Therapeutics HALO:US USD 130.79M 21.4M
Insmed INSM:US USD 190.24M 52.59M
Intercept Pharmaceuticals ICPT:US USD 230.08M 8.49M
Neurocrine Biosciences NBIX:US USD 537.7M 52.6M
Ptc Therapeutics PTCT:US USD 406.24M 13.84M
Sarepta Therapeutics SRPT:US USD 619.6M 16.69M
Ultragenyx Pharmaceutical RARE:US USD 261.21M 33.85M
United Therapeutics UTHR:US USD 343.2M 27.3M
YTE INCY:US USD 1.16B 150.48M